Clinical TrialsSearch results
Number of results: 68732
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III study of Rituximab in Patients with Systemic Lupus Erythematosus
- Systemic lupus erythematosus
- Zenyaku Kogyo Co., Ltd.
- 2007-03-16
Other
- Clinical study of Rituximab for inhibition of antibody mediated rejection in ABO-incompatible kidney transplantation
- Chronic kidney disease patient to whom ABO incompatibility kidney transplantation is planned.
- Zenyaku Kogyo Co., Ltd.
- 2011-11-01
Other
- Japanese phase II study in untreated patients with CD20 positive B-cell non-Hodgkin's lymphoma evaluating safety of 90-minute infusion of rituximab.
- CD20 positive follicular lymphoma or diffuse large B-cell lymphoma.
- ZENYAKU KOGYO CO., LTD.
- 2017-08-01
Other
- Phase II study of rituximab in patients with severe systemic lupus erythematosus
- Systemic lupus erythematosus
- Zenyaku Kogyo Co., Ltd.
- 2007-07-05
Other
- Phase II study of Rituximab in Patients with Systemic Lupus Erythematosus
- Systemic lupus erythematosus
- Zenyaku Kogyo Co., Ltd.
- 2007-07-05
Other
- Phase II study of rituximab in refractory or relapsed patients with multiple myeloma expressing CD20
- Multiple myeloma expressing CD20
- Zenyaku Kogyo Co., Ltd.
- 2006-11-28
Other
- Phase III study for evaluating efficacy and safety of a combination treatment of IDEC-C2B8 with steroid pulse therapy and plasmapheresis for antibody-mediated rejection after kidney transplant.
- Antibody-mediated rejection (ABMR) after living or cadaveric kidney transplant.
- ZENYAKU KOGYO CO., LTD.
- 2018-10-23
Other
- Phase III study for evaluating efficacy and safety of desensitization based on IDEC-C2B8 in living donor kidney transplantation recipients with pre-formed anti-HLA antibody and/or donor-specific antibody. Phase III study for evaluating efficacy, safety and pharmacokinetics of pre-transplant administration of FK506 or FK506E(MR4) for 7 to 28 days in living donor kidney transplantation recipients.
- Living donor kidney transplantation recipients with pre-formed anti-HLA antibody and/or donor-specific antibody.
- ZENYAKU KOGYO CO., LTD.
- 2018-10-23
Other
- Post-marketing clinical study of rituximab monotherapy at eight weekly infusions in relapsed or refractory patients with indolent B-cell non-Hodgkin's lymphoma
- Indolent non Hodgkin's lymphomas
- Zenyaku Kogyo Co., Ltd.
- 2010-01-05
Other
- Rituxan injection specific drug use-results survey
- Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA)
- Zenyaku Kogyo Co., Ltd.
- 2013-09-01